National Institute on Drug Abuse-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:National Institute on Drug Abuse - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014108
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine, prescription drugs, commonly abused drugs, emerging trends, salvia, and tobacco addiction, among others. It also offers services in addiction science, drug testing, drugged driving, global health, hepatitis, comorbidity, criminal justice and drug abuse areas. The institute operates AIDS research program, international program, and intramural research program, among others. NIDA is headquartered in Bethesda, Maryland, the US.

National Institute on Drug Abuse – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 10
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 11
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Licensing Agreements 15
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 15
National Institute on Drug Abuse – Key Competitors 16
National Institute on Drug Abuse – Key Employees 17
National Institute on Drug Abuse – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Government and Public Interest 19
Nov 01, 2017: Understanding Addiction in the Adolescent Mind 19
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 21
Sep 27, 2017: Camino Pharma Co-founder Receives $10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 23
Sep 15, 2017: Immune System Linked to Alcohol Drinking Behaviour 24
Aug 01, 2017: Collins, King Announce $185,413 in Funding to the University of New England to Support Addiction Research 26
Jan 30, 2017: New TSRI Study Shows Early Brain Changes in Fragile X Syndrome 27
Oct 13, 2016: Scripps Florida Scientists Awarded Special Grant to Develop Memory-Altering Medication for Addiction 28
Oct 07, 2016: Researchers find novel function for old protein in work that could lead to new ways to protect brain from stroke damage 29
Aug 08, 2016: NIH Grant To Fund New Center For Systems Neurogenetics Of Addiction 30
Jul 27, 2016: Infusion of Nearly $35.4 Million in Grant Funding to Support Roswell Park Research 31
Jun 28, 2016: UAMS Receives NIH Grant for First Comprehensive Study of Synthetic Marijuana Dangers 33
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Key Facts 2
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
National Institute on Drug Abuse, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
National Institute on Drug Abuse, Deals By Therapy Area, 2011 to YTD 2017 8
National Institute on Drug Abuse, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 10
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 11
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 12
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 13
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 14
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 15
National Institute on Drug Abuse, Key Competitors 16
National Institute on Drug Abuse, Key Employees 17

★海外企業調査レポート[National Institute on Drug Abuse-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Instituto Costarricense de Electricidad:企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Pacific Mutual Holding Company:企業の戦略的SWOT分析
    Pacific Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Kunlun Energy Co Ltd (135):石油・ガス:M&Aディール及び事業提携情報
    Summary Kunlun Energy Co Ltd (Kunlun), formerly CNPC (Hong Kong) Ltd, a subsidiary of PetroChina Company Ltd, is an integrated oil and gas company that explores and produces crude oil and natural gas. The company also operates natural gas pipelines, LNG processing and storage facilities and conducts …
  • OrthoPediatrics Corp (KIDS):医療機器:M&Aディール及び事業提携情報
    Summary OrthoPediatrics Corp (OrthoPediatrics) is a medical device company that designs, develops and distributes implants and instruments. The company offers trauma and deformity, spine, sports medicine, and clinical education products. It provides cannulated screws, spine system, ACL reconstructio …
  • Empire Genomics LLC:医療機器:M&Aディール及び事業提携情報
    Summary Empire Genomics LLC (Genomics) is a medical device company that offers clinical molecular diagnostic solutions. The company provides ID labs products, fish probes, BAC clones, and genotyping and circulating tumor cell products. Its ID lab products include cytogenetics media, cytogenetics pro …
  • Harvard Bioscience Inc (HBIO):企業の財務・戦略的SWOT分析
    Harvard Bioscience Inc (HBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • GS Engineering & Construction Corp (006360):企業の財務・戦略的SWOT分析
    GS Engineering & Construction Corp (006360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Expeditors International of Washington, Inc.:企業の戦略・SWOT・財務分析
    Expeditors International of Washington, Inc. - Strategy, SWOT and Corporate Finance Report Summary Expeditors International of Washington, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Quanta Computer Inc (2382):企業の財務・戦略的SWOT分析
    Quanta Computer Inc (2382) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Numab Innovation AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Numab Innovation AG (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company’s pipeline products include ND007, ND009, ND016, ND017, ND023, ND026, and ND021. Its ND007 is a bispecific antibody fragment which is being evaluated for the treatment of autoim …
  • Empresa Electricidad del Peru SA (ELECPBC1):企業の財務・戦略的SWOT分析
    Empresa Electricidad del Peru SA (ELECPBC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • BGFIBank Group:企業の戦略・SWOT・財務分析
    BGFIBank Group - Strategy, SWOT and Corporate Finance Report Summary BGFIBank Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Imperial Brands Plc:企業の戦略・SWOT・財務情報
    Imperial Brands Plc - Strategy, SWOT and Corporate Finance Report Summary Imperial Brands Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ECO Animal Health Group Plc (EAH):企業の財務・戦略的SWOT分析
    Summary ECO Animal Health Group Plc (ECO) is a veterinary products manufacturer that offers therapeutic products. The company develops, registers and markets pharmaceutical products and chemicals for animal health markets. ECO produces proprietary patented drugs that are used for the treatment of re …
  • DURECT Corp (DRRX)-製薬・医療分野:企業M&A・提携分析
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • Adaptive Biotechnologies Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptive Biotechnologies Corp (Adaptive) specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company’s product portfolio comprises immunoSEQ and clonoSEQ. It provides immunosequencing platform to laboratories for conductin …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, creative, photography and design, games, advertising and film and music. It provides licensing and syndication, expo …
  • GreenShift Corp (GERS):企業の財務・戦略的SWOT分析
    Summary GreenShift Corp (GreenShift) is an engineering and technology company that develops, invents, and commercializes renewable and clean technologies. It offers services such as marketing, construction and engineering services. Its construction and engineering services comprise engineering innov …
  • Aesica Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Aesica Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Korean Air Lines Co Ltd:企業の戦略・SWOT・財務分析
    Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆